Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial-Reference-Cited by-同舟云学术

Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial

Published:2021-02 Issue:2 Volume:32 Page:218-228
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Xu B.,Sun T.,Zhang Q.,Zhang P.,Yuan Z.,Jiang Z.,Wang X.,Cui S.,Teng Y.,Hu X.-C.,Yang J.,Pan H.,Tong Z.,Li H.,Yao Q.,Wang Y.,Yin Y.,Sun P.,Zheng H.,Cheng J.,Lu J.,Zhang B.,Geng C.,Liu J.,Shen K.,Yu S.,Li H.,Tang L.,Qiu R.

Funder

Beijing Biostar Technologies

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. Extending survival with chemotherapy in metastatic breast cancer;O’Shaughnessy;Oncologist,2005

2. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015);Cardoso;Breast,2018

3. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4);Cardoso;Ann Oncol,2018

4. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action;Bollag;Cancer Res,1995

5. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells;Giannakakou;Proc Natl Acad Sci USA,2000

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple-negative breast cancer survival prediction: population-based research using the SEER database and an external validation cohort;Frontiers in Oncology;2024-06-10

2. The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer;Frontiers in Pharmacology;2024-03-04

3. In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer;Handbook of Experimental Pharmacology;2024

4. Research Progress of Ebomycin Antitumor Drugs in Breast Cancer;Hans Journal of Medicinal Chemistry;2024

5. Research Progress in First-Line Treatment for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer;Advances in Clinical Medicine;2024